CNN Anthony Fauci LYING on national television - with Lou Dobbs, saying, we
have a Lyme vaccine
"We've had an effective vaccine,
but it's the kind of vaccine that you
have to essentially vaccinate people
each year. And from the standpoint of
it's use, it has not been used as
efficiently as it could have been used.
So scientifically, we had a vaccine and
still do have a vaccine, but it's not
really well used." -- Fauci
That was after the vaccine
had already been removed from the market because of Tuft's publication in a
patent that OspA binds the HLA molecule or is a superantigen or toxin in some
people. See the Patents video for the patent number.
DOBBS: And, of course, the
concerning, the frightening aspect of
this is that doctors today are not Lyme
disease literate and still have not come
up with effective treatments and yet we
see new diseases emerging here.
DOBBS: Louise, thank you very much.
Louise Schiavone from Washington.
Dr. Anthony Fauci is director of the
National Institutes for Health. He says
emerging diseases are noting new.
They're spread not surprising given the
nature of a shrinking world in which we
all now live. Dr. Anthony Fauci joins us
now from Washington. Good to have you
DR. ANTHONY FAUCI, DIRECTOR, NIH: Good
to be here.
DOBBS: This week, Doctor, we have been
focusing on this show on emerging
diseases and it is concerning. With
international travel, with the number of
diseases that are emerging, how would
you rank the level of concern on the
part of your organization and other
public health agencies?
FAUCI: Well, it's a level of concern
that spurs you to be very vigilant to
increase your preparedness. It's not the
kind of concern where you wring your
hands and feel panicky that you have an
impending disaster that it's just around
the corner, but it is a state of mind of
taking it very seriously.
Emerging and reemerging diseases have
been with us from the beginning of
civilization and will continue to be
with us because of that special
relationship between microbes and
humans, and they emerge. They emerge as
new diseases or they reemerge as older
diseases, only under different forms.
DOBBS: The capacity, though, by which
they can be transmitted, to populations
centers literally all over the planet is
entirely new. And amongst those
diseases, Dr. Fauci, which is the most
concerning to you? Which do you think
deserves the highest priority on the
part of U.S. public health officials?
FAUCI: Well, Lou , right now, the
unknown is certainly something that you
can't quantitate because we could have
the emergence of a disease like SARS of
which we are still having a problem with
right now. Although it's plateaued
that's a totally new disease. So there's
a vast unknown.
But of the things that we know of that
most concerning to many public health
officials like myself is a pandemic
influenza because we know in that 1918,
influenza killed 40 or some odd more
million people worldwide, and about
750,000 people in the United States in
one year, in 1918. And there certainly
is a possibility that we may have the
emergence of, again, another pandemic,
So that's of considerable concern to me.
DOBBS: Debilitating, as well, but of a
lesser threat in terms of its fatality
rate, its mortality rate, is lyme
disease. It is striking that in a period
of 30 years, treatment is so -- if you
will, primitive. Cures not at hand.
Diagnosis is often not available. Too
many doctors simply not literate. How
can this be?
FAUCI: Well, that's exactly not quite
the case, Lou. In lyme disease, if you
get acute lyme disease, the antibiotic
treatment of that is really quite
effective in curing people of it. What
happens that sometimes it goes
undiagnosed or it goes into into a
chronic form. And once it goes into a
chronic form, then you have a
We've had an effective vaccine, but
it's the kind of vaccine that you have
to essentially vaccinate people each
year. And from the standpoint of it's
use, it has not been used as efficiently
as it could have been used. So
scientifically, we had a vaccine and
still do have a vaccine, but it's not
really well used.
The problem is when you get either an
undiagnosed case that goes on smoldering
without appropriate treatment or you get
into the chronic phase which can be
DOBBS: And turning to West Nile virus,
we are coming into -- May and June,
record wet weeks in the east. Mosquitoes
will be certainly in abundance. And West
Nile, the danger from it even greater.
How concerned are you about West Nile
FAUCI: Certainly West Nile is of
concern. Remember, it came for the first
time in the United States in 1999 just a
handfuls of cases. Last year, we had
over 4,100 cases with 285 deaths.
When you have the seasons like we have
now with the wetness and then you have a
following a dry season, we'll wind up
with some significant problems. I don't
think there's any doubt. We have already
identified in about 24 states animals
that have already been this season
identified to be infected with West
Nile. That's a bad sign.
So we're girding ourselves with a good
deal of surveillance and we may have to
implement some significant mosquito
control measures depending on how things
shake out over the next couple of
months. So it's something we need to
keep a very serious eye on.
DOBBS: Dr. Anthony Fauci of the National
Institutes of Health, we thank you very
much for being with us.
Thanks, Fauc'. This may be
the antidote to Neuroborreliosis (The Mark
Klempner Seronegative kind), and
post LymeRIX syndrome (Immune
FIELD OF THE INVENTION
The present invention pertains to a
method for activating the immune system
of a patient by intermittently
administering interleukin-2 (IL-2) to
that patient. Such administration of
IL-2 can optionally be combined with
other therapies, such as
anti-retroviral, anti-bacterial or
anti-fungal therapies, suitable for
treatment of the patient's condition.
This invention also relates to an
approach to gene therapy that entails
administering IL-2 to a patient so as to
facilitate in situ lymphocyte
transduction by a retroviral vector also
administered to the patient.
BACKTGROUND OF THE INVENTION
Attempts at immune activation and
restoration in the past have utilized
bone marrow transplantation or
lymphocyte transfers (H. C. Lane et al.,
Ann. Internal Med. 113: 512-19 (1990)),
immunomodulating agents such as
immuthiol (J. M. Lang et al., Lancet 24:
702-06 (1988)) or isoprinosine (C.
Pedersen et al., N. Engl. J. Med. 322:
1757-63 (1990)), and recombinant
cytokines such as interferon alpha (IFN-.alpha.)
and IL-2. H. C. Lane et al., Ann.
Intern. Med. 112: 805-11 (1990); H. C.
Lane et al., J. Biol. Response Mod. 3,
512-16 (1984); D. H. Schwartz et al., J.
Acquir. Immune Defic. Syndr. 4, 11-23
(1991); P. Mazza et al., Eur. J.
Haematol. 49: 1-6 (1992); H. W. Murray
et al., Am. J. Med. 93: 234 (1992); H.
Teppler et al., J. Infect. Dis. 167:
291-98 (1993); P. Volberding et al.,
AIDS Res. Hum. Retroviruses 3: 115-24
(1987). These studies have resulted in
minimal or only transient immune system
The use of biologic response modifiers
in general, and of IL-2 in particular,
is an active area of clinical research.
Interleukin-2 is a T cell-derived
lymphokine with a number of
immunomodulating effects including
activation, as well as induction of
proliferation and differentiation, of
both T and B lymphocytes. K. A. Smith,
Science 140: 1169-76 (1988). Exogenous
IL-2 has been shown in vitro to increase
the depressed natural killer cell
activity and cytomegalovirus-specific
cytotoxicity of peripheral blood
mononuclear cells from patients with
AIDS, as well as to increase IFN-.gamma.
production by lymphocytes from patients
with AIDS. A. H. Rook et al., J. Clin.
Invest. 72: 398-403 (1983); H. W. Murray
et al., loc. cit. 76: 1959-64 (1985).
IL-2 given by high dose infusion has
been employed in the treatment of renal
cell carcinoma and melanoma. J. Nat'l
Cancer Inst. 85(8): 622-32 (1993). For
example, doses of 36 million
international units (MU) given
continuously over a period of 24 hours
has been used in the treatment of cancer
(18 MU is equivalent to about 1 mg
protein). Lancet 340: 241 (1992). The
use of high doses of IL-2 generally is
not well tolerated by patients, however,
and side effects are more pronounced at
such high levels.
"If you want to talk about ethics,"
said Dr. Anthony Fauci of the National
Institutes of Health in Maryland, "you
want to make sure something works before
you announce it."
ROTFL, Yeahright, ethics.
The conduct of
Dr. Fauci, and others, has compromised
the basic principles of ethics, public
trust and the most fundamental concepts
that define "scientific integrity".
"The conduct of Dr. Fauci, and others, has compromised
the basic principles of ethics, public trust and the most fundamental concepts
that define 'scientific integrity'. "
Greater potential to transmit HIV congenitally if you are black:
Does this account for the ineptitude in the development of an HIV vaccine?